trial summary · NCT06791057
Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
Trial record from the TrialBase DB dataset, status RECRUITING, condition Advanced Lung Cancer, sponsored by Massachusetts General Hospital. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
Dyspnea, or breathlessness, is one of the most common and distressing symptoms experienced by patients with advanced lung cancer. The purpose of this multi-site trial is to test the effectiveness of a dyspnea intervention (called BREEZE+) that includes three brief nurse-delivered sessions and access to a digital health app that teaches and reinforces patients' use of skills for managing and coping with this highly debilitating symptom. This study will lay the groundwork for a follow-up pragmatic implementation trial integrating BREEZE+ into usual oncology care for patients with advanced lung cancer experiencing dyspnea.
Source record: https://clinicaltrials.gov/study/NCT06791057
Facts
| registry id | NCT06791057 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | not reported |
| study type | INTERVENTIONAL |
| lead condition | Advanced Lung Cancer |
| sponsor | Massachusetts General Hospital |
| sponsor class | OTHER |
| enrollment | 420 |
| start date | 2026-11-01 |
| primary completion | 2030-12-31 |
| completion | 2031-06-30 |
| results posted | not reported |
Conditions
- Advanced Lung Cancer
- Dyspnea
Interventions
- Dyspnea Intervention
- Enhanced Usual Care
Countries
- United States
Intervention types: BEHAVIORAL
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.